FDA Invites Comments on Food Additive Petition Forms
Published Date: 4/10/2026
Notice
Summary
The FDA wants your thoughts on how they collect info when companies ask to add or label food and color additives. This includes using a special online form to make submissions easier. If you’re involved in food safety or labeling, now’s the time to speak up before June 9, 2026—no extra costs, just your feedback!
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Color Additive Petition Fees
If your business files a color additive petition (CAP), listing fees range from $1,600 to $3,000 depending on use. FDA expects an average of four CAPs per year (one Category A and one Category B on average), with maximum Category A fee $2,600 and maximum Category B fee $3,000; FDA estimates total annual operating costs to petitioners of up to $11,200 ((2 x $2,600) + (2 x $3,000)).
Time Burden to Prepare Petitions
FDA estimates the annual reporting burden for these petitions at 26,632 hours total. The table shows average burden per response of 1,337 hours for color additive petitions (4 responses) and 7,093 hours for food additive petitions (3 responses); FDA also states burden increased by 2,674 hours due to more CAP submissions over the last 10 years.
Electronic Submission Tools Reduce Paperwork
FDA offers electronic submission options: the Centralized Online Submission Module (COSM) is a 24/7 web tool that supports electronic submissions and eliminates the need to print and mail paper petitions. Form FDA 3503 helps organize petition content, and master files can be used as repositories to reference information across multiple submissions to minimize paperwork burden.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-06934, Agency Information Collection Activities; Submission for OMB Review; Comment Request; Extension: Rule 22e-4
The SEC is asking to keep collecting info from certain investment funds about how they manage the risk of not being able to quickly sell their investments. This affects open-end funds and special ETFs that trade by swapping assets. The goal? To make sure these funds stay ready to pay investors on time without messing with their money, with no new costs or deadlines added.
Next: 2026-06936, Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification
The FDA wants your thoughts on how they collect info about color additive certifications, which help keep our food and products safe and colorful. This is a chance for companies and the public to comment on the current process before it continues. You’ve got until June 9, 2026, to share your ideas—no cost changes are mentioned, just a smooth info check-in!